JNJJohnson & Johnson

Next report: No date yet; none in the next 8 weeks
Last result: $2.59Beat; vs $2.53 expected on Oct 13
Stock move on it: −5.73%; one session
Typical move: ±4.2%; average over 2 reports
Price: $283.56; +1.12% today · $659B cap

Past and upcoming reports


Oct 13, 2026	Sep 30, 2026	Time not given	$2.53	Beat$2.59	Beat+2.4%	−5.73%
Jul 15, 2026	Jun 30, 2026	Time not given	$2.84	Beat$2.90	Beat+2.1%	−2.69%

After the report

Jul 15, 2026 report

This covers the Jul 15, 2026 report. The Oct 13, 2026 numbers are in the table above.

JNJ beats Q2 EPS, raises FY2026 guidance. stock rallies on defensive rotation

JNJ reported Q2 EPS of $2.90, beating the $2.84 consensus by 2.1%. Management raised full-year 2026 guidance, accelerating a defensive rotation into the stock. Shares rose 1.23% to $253.04.

Reported against expected

Beat

Beat: reported EPS $2.90 vs estimated $2.84 (surprise +2.1%)

Guidance

Raised

Positive: raised 2026 guidance (from stock_intelligence 'Raised guidance and rotation lift JNJ after miss')

How the stock reacted

+1.23% on report day (close $253.04), volume 7.5M shares

What changed

EPS beat by 2.1% and FY2026 guidance raised

What the price now assumes

Rotation into defensives with raised guidance supporting a hold thesis

What it means for the business

Upgrade bias. watch Stelara trajectory for sustained revenue confidence

The next one to three months, as we saw it then

Better case25%

Pipeline growth (e.g., Talquetamab, Carvykti) accelerates and Stelara decline stabilizes, driving upward guidance revisions and multiple expansion

Base case55%

JNJ executes on raised guidance, steady defensive cash flows, but limited upside given stretched forward P/E (19.9x vs sector 18.1x)

Worse case20%

Stelara biosimilar erosion outpaces expectations, MedTech segment disappoints, and forward P/E de-rates toward sector average

If you hold it

Hold unless Stelara quarterly sales decline >15% YoY. trim if forward P/E exceeds 22x on no new catalyst

If you are watching

Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.

Scenario odds are a judgement, not measured.